| Page 1219 | Kisaco Research
 

Andrew Voysey

Head of Impact and Carbon
Soil Capital

Andrew is Head of Impact and Carbon at Soil Capital, the regenerative agronomy firm that launched Europe’s first certified, multinational carbon payment programme for farmers in 2020.

Andrew led the development of this programme, called Soil Capital Carbon, which has now enrolled more than 500 British, French and Belgian farmers. The programme has recently paid out nearly 1 million Euros to farmers for their first year's performance, with the majority of those payments coming from food and agri businesses within the supply chain.

Andrew Voysey

Head of Impact and Carbon
Soil Capital

Andrew Voysey

Head of Impact and Carbon
Soil Capital

Andrew is Head of Impact and Carbon at Soil Capital, the regenerative agronomy firm that launched Europe’s first certified, multinational carbon payment programme for farmers in 2020.

Andrew led the development of this programme, called Soil Capital Carbon, which has now enrolled more than 500 British, French and Belgian farmers. The programme has recently paid out nearly 1 million Euros to farmers for their first year's performance, with the majority of those payments coming from food and agri businesses within the supply chain.

Soil Capital began life as an independent agronomy firm specialised in helping farmers improve farm profitability through transitions to regenerative agriculture. This activity continues through a separate entity, Soil Capital Farming, now with a track record across more than 200,000 hectares and 21 countries. Prior to Soil Capital, Andrew spent a decade building the sustainable finance practice at the University of Cambridge Institute for Sustainability Leadership. During this time, he led several industry collaborations between the finance and food and farming sectors and was an advisor on climate change at the Bank of England.

 

Kimberly Schluns

Senior Director
Research, Kite Pharma

Kimberly Schluns

Senior Director
Research, Kite Pharma

Kimberly Schluns

Senior Director
Research, Kite Pharma
 

David Vereide

iPSC Lead
Umoja Biopharma

David Vereide

iPSC Lead
Umoja Biopharma

David Vereide

iPSC Lead
Umoja Biopharma

ESG Testimonial 2

I was sent to this event to learn how our organization can begin the journey that is ESG. Without knowing what to expect, I came away with a wide array of knowledge, best practices, and practical applications that will help my organization achieve ESG goals. Every delegate, speaker, and panelist I met were well informed and shared their knowledge and experience with me. And I met some colleagues that I can count on to share ESG information and best practices for the future. We are all in this together and that was a central theme of this program.

 

Teisha Rowland

iPSC Lead
Umoja Biopharma

Teisha Rowland

iPSC Lead
Umoja Biopharma

Teisha Rowland

iPSC Lead
Umoja Biopharma
 

Lan Cao

VP, Head of Cell Therapy Innovation Group
Takeda

Lan Cao

VP, Head of Cell Therapy Innovation Group
Takeda

Lan Cao

VP, Head of Cell Therapy Innovation Group
Takeda
 

Mark Plavsic

Chief Technical Officer
Fate Therapeutics

Mark Plavsic

Chief Technical Officer
Fate Therapeutics

Mark Plavsic

Chief Technical Officer
Fate Therapeutics
 

Allison Hubel

Director
Technological Leadership Institute, University of Minnesota

Allison Hubel

Director
Technological Leadership Institute, University of Minnesota

Allison Hubel

Director
Technological Leadership Institute, University of Minnesota

ESG Testimonial 1

The summit was fantastic! The speakers were well selected, and the presentations were helpful especially as I begin viewing our business through the ESG lens.

 

Stefan Frank

Associate Director iPSC Platform Strategy
Bayer

Stefan Frank

Associate Director iPSC Platform Strategy
Bayer

Stefan Frank

Associate Director iPSC Platform Strategy
Bayer